Lecithin–cholesterol acyltransferase (LCAT, also called phosphatidylcholine–sterol O-acyltransferase) is an enzyme found in many animals, including humans. It converts free …

Lecithin cholesterol acyltransferase (LCAT) (EC2.3.1.43), a lipoprotein-associated enzyme, is a key player in the reverse cholesterol transport (RCT) pathway, which promotes the transfer of …

Mar 1, 2022 · In this review, we discuss the diseases associated with LCAT and therapies that use LCAT as a target hoping to find out whether LCAT can be an effective therapeutic target …

The ultimate goal of AlphaCore Pharma is to develop LCAT infusion as an acute therapy for unstable plaque and atherosclerosis. PUBLIC HEALTH R ELEVANCE: Coronary heart …

LCAT is a plasma enzyme that raises high-density lipoprotein (HDL) levels in plasma and may protect against atherosclerosis. LCAT is defective in patients with Familial LCAT Deficiency …

LCAT converts free cholesterol to cholesteryl esters in the process of reverse cholesterol transport. Familial LCAT deficiency (FLD) is a genetic disease that was first described by …

LCAT plays a key role in the maturation of HDL, as evidenced by low HDL-cholesterol levels in carriers of deleterious mutations in LCAT. However, the role of LCAT in atherosclerosis is …

We discuss the latest findings on the biochemistry of lecithin: cholesterol acyltransferase (LCAT), the effect of LCAT on atherosclerosis, clinical features of LCAT deficiency, and the impact of …

Lecithin:cholesterol acyltransferase (LCAT) is a plasma enzyme that esterifies cholesterol. Recombinant human LCAT (rhLCAT) is now being developed as an enzyme replacement …

Aug 3, 2009 · The third monogenic cause of extremely low HDL-C is lecithin:cholesterol acyltransferase (LCAT) deficiency, a form of which is also known as fish-eye disease.